Pravastatin and Gemfibrozil Interaction
Drug interaction information between Pravastatin and Gemfibrozil.
Pravastatin and Gemfibrozil have a documented moderate interaction in FDA labeling.
FDA drug labeling documents a moderate-severity interaction between Pravastatin and Gemfibrozil. Major interactions are generally avoided, moderate ones may need monitoring or a dose adjustment, and minor ones are usually low-risk. This page shows the documented mechanism and guidance. Label-documented interactions are not a complete safety review, so always confirm your own medications with a pharmacist or doctor. Educational information, not medical advice.
How They Interact
Using these medications at the same time significantly raises the risk of serious muscle injury and breakdown.
What To Do
You should avoid taking these two medications together. Talk to your doctor about alternative treatment options.
FDA Label Information
7.4 Gemfibrozil Due to an increased risk of myopathy/rhabdomyolysis when HMG-CoA reductase inhibitors are coadministered with gemfibrozil, concomitant administration of Pravastatin Sodium with gemfibrozil should be avoided [see Warnings and Precautions (5.1) ]. 7.4 Gemfibrozil Due to an increased risk of myopathy/rhabdomyolysis when HMG-CoA reductase inhibitors are coadministered with gemfibrozil, concomitant administration of Pravastatin Sodium with gemfibrozil should be avoided [see Warnings and Precautions (5.1) ].
Pravastatin Also Interacts With
- Cyclosporine moderate
- Erythromycin moderate
- Clarithromycin moderate
- Colchicine moderate
- Niacin moderate
Gemfibrozil Also Interacts With
- Ezetimibe major
- Ezetimibe/Simvastatin major
- Repaglinide major
- Simvastatin major
- Atorvastatin moderate
Frequently Asked Questions
Can I take Pravastatin and Gemfibrozil together?
This is a moderate interaction. You should avoid taking these two medications together. Talk to your doctor about alternative treatment options.
How serious is the interaction between Pravastatin and Gemfibrozil?
This interaction is classified as "moderate" severity by the FDA. Moderate interactions may worsen your condition or change how your medications work.
Why do Pravastatin and Gemfibrozil interact?
Using these medications at the same time significantly raises the risk of serious muscle injury and breakdown.
Understanding the Pravastatin and Gemfibrozil Interaction
FDA-approved prescribing information for these two drugs flags their combination as a moderate-severity interaction. Pravastatin belongs to the HMG-CoA Reductase Inhibitor (Statin) class and Gemfibrozil belongs to the Fibrate class - two categories that can collide when co-prescribed. The mechanism described in FDA labeling is: Using these medications at the same time significantly raises the risk of serious muscle injury and breakdown. Severity tiers matter: major flags generally advise avoidance, moderate flags often require monitoring or dose adjustment, and minor flags may only call for awareness.
Context around a specific patient determines real-world impact. Pravastatin has 16 total documented interactions on file in this dataset, and Gemfibrozil has 20. Each additional medication compounds the interaction surface, which is why pharmacists run full-profile checks rather than evaluating one pair at a time. FDA-derived guidance for this pair is: You should avoid taking these two medications together. Timing of doses, renal and hepatic function, age, and other concurrent prescriptions all shape whether a labeled interaction matters clinically.
An interaction flag is not a verdict. A large share of labeled interactions are managed routinely in clinical practice, the fix may be as simple as spacing doses or adding a monitoring test. Others require the prescriber to choose a different medication entirely. This page surfaces FDA-sourced labeling and openFDA data for educational purposes only; it is not medical advice and cannot account for your full clinical picture. Never start, stop, or adjust either Pravastatin or Gemfibrozil based on a web page, speak with your prescriber or pharmacist before making any change.
Sources: FDA Drug Labels (SPL) via openFDA (2026). This is for informational purposes only and is not medical advice. Always consult your healthcare provider about drug interactions.
Read our methodology - how this data is sourced, computed, and verified.